Skip to content

Nikhita Singhal

6 papers in the library · 381 citations · publishing 2020-2024

Papers

Sort Most recent Most cited

A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.

Psychedelic Med (New Rochelle) March 12, 2024 Alexander Wen, Nikhita Singhal, Brett D. M. Jones et al. 36 citations

Introduction: Effective blinding is especially challenging in randomized controlled trials (RCTs) involving psychedelics due to the inherent alterations in consciousness that these compounds induce. In this systematic review and exploratory analysis, we aim at synthesizing the methodologies used in RCTs involving classic psychedelics and identify procedures that can help minimize unblinding and...

Corrigendum to “Decreases in Suicidality Following Psychedelic Therapy

The Journal of Clinical Psychiatry May 9, 2022 Richard J. Zeifman, Dengdeng Yu, Nikhita Singhal et al. 2 citations correction

To the Editor: Our group recently published in JCP the first meta-analysis of patient-level data on the effects of psychedelics on suicidality. 1 While not described in our article, it is noteworthy that 2 suicidality-related events that had been deemed not attributable to the administration of a psychedelic (by the authors of the primary outcome studies) occurred within the studies included in...

Decreases in Suicidality Following Psychedelic Therapy

The Journal of Clinical Psychiatry January 13, 2022 Richard J. Zeifman, Dengdeng Yu, Nikhita Singhal et al. 18 citations

Objective: Suicide is a global health concern, and innovative interventions that target suicidality are needed. While psychedelic therapy shows promise for a range of mental health concerns, including suicidality, not all psychedelic therapy trials have published their suicidality results and no meta-analysis has been published on the topic. Therefore, we completed the first meta-analysis of...

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review

ACS Pharmacology & Translational Science March 11, 2021 Richard J. Zeifman, Nikhita Singhal, Leah Breslow et al. 60 citations

Use of classic psychedelics (e.g., psilocybin, ayahuasca, and lysergic acid diethylamide) is increasing, and psychedelic therapy is receiving growing attention as a novel mental health intervention. Suicidality remains a potential safety concern associated with classic psychedelics and is, concurrently, a mental health concern that psychedelic therapy may show promise in targeting. Accordingly,...

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial.

Psychopharmacology February 1, 2021 Richard J. Zeifman, Nikhita Singhal, Rafael G. Dos Santos et al. 79 citations

Suicidality is a major public health concern with limited treatment options. Accordingly, there is a need for innovative interventions for suicidality. Preliminary evidence indicates that treatment with the psychedelic ayahuasca may lead to decreases in depressive symptoms among individuals with major depressive disorder (MDD). However, there remains limited understanding of whether ayahuasca...

The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.

Journal of Affective Disorders November 1, 2020 Roger S McIntyre, Isabelle P. Carvalho, Leanna M.W. Lui et al. 186 citations

BACKGROUND Ketamine is established as a rapid and effective treatment in adults with treatment-resistant depression (TRD). The availability of different formulations and routes of delivery invites the need for evaluating relative effect sizes. METHODS Effect size with respect to depression symptom reduction for each formulation and route of delivery was compared at discrete time-points (i.e.,...